|
Getting your Trinity Audio player ready...
|
A new wave of innovation is taking hold across the biotech and tech sectors, with four high-impact companies—Peraso Inc. (NASDAQ: PRSO), Lexicon Pharmaceuticals (NASDAQ: LXRX), Portage Biotech (NASDAQ: PRTG), and TransCode Therapeutics (NASDAQ: RNAZ)—each making strategic advances in their respective arenas: military-grade wireless, obesity treatment, cancer immunotherapy, and RNA-based oncology solutions. These breakthroughs represent critical inflection points for investors eyeing cutting-edge solutions backed by scientific validation, regulatory momentum, and untapped market potential.
Peraso Inc. (NASDAQ: PRSO), a leader in millimeter wave (mmWave) technology, is targeting and advancing into the military wireless space—long dominated by legacy defense firms. Leveraging its patented 60GHz mmWave solutions, Peraso aims to deliver secure, high-speed communications across UAVs, radar systems, and battlefield networks.
The company holds key IP, including patents addressing interference management and beamforming antenna systems, giving it a tactical edge in next-gen defense communications. As global defense systems shift to next-gen wireless, demand for cost-effective, license-free mmWave connectivity is surging—positioning Peraso as a frontrunner ahead of larger, slower-moving competitors.
“Peraso’s mmWave platform offers a strong alternative to traditional RF systems,” said an industry analyst. CEO Ron Glibbery recently discussed the company’s strategy on The Street Reports Podcast , listen now.
With growing defense budgets and emphasis on unlicensed, high-throughput tech, Peraso is building long-term value in a rapidly evolving market—emerging as a high-potential wireless stock aligned with modern battlefield needs.
Lexicon Pharmaceuticals (Nasdaq: LXRX) has signed a global licensing deal with Novo Nordisk for its oral obesity drug candidate LX9851, potentially worth up to $1 billion, including $75 million in upfront and near-term milestones. LX9851, which targets the ACSL5 enzyme, has shown strong preclinical results, especially when paired with semaglutide. Novo Nordisk will handle development and commercialization, while Lexicon is eligible for tiered royalties on sales.
Portage Biotech (NASDAQ: PRTG) reported breakthrough preclinical results for PORT-7, showing over 90% tumor reduction in mesothelioma models when combined with an anti-PD-1 antibody. Presented at the 2025 ELCC in Paris, the data marks the first evidence of selective A2B inhibition efficacy in this cancer type. Portage plans to launch a first-in-human trial and is also advancing PORT-6, a selective A2A inhibitor, with plans to combine both agents in the ADPORT-601 trial for enhanced immunotherapy impact.
TransCode Therapeutics (NASDAQ: RNAZ) has dosed the first patient in Cohort 4 of its Phase 1 trial for TTX-MC138, an RNA therapy targeting metastatic cancer via microRNA-10b inhibition. Ten patients have been treated so far with no major safety issues. The latest dose is 50% higher than in the previous cohort, with more patients being evaluated for enrollment.
The story of Signal Advance, Inc. (OTC: SIGL) — from a viral stock surge sparked by Elon Musk’s “Use Signal” tweet to its current evolution as a cybersecurity innovator — reflects both the unpredictability of social media-driven markets and the company’s determination to build lasting value beyond the meme.Read now.
From Peraso’s patent-backed 60GHz mmWave wireless tech gaining traction in military communications, to Lexicon’s $1B obesity licensing deal with Novo Nordisk, Portage’s novel adenosine pathway immunotherapy in mesothelioma, and TransCode’s advancement of RNA cancer therapeutics with no safety red flags—these emerging players are reshaping their sectors with disruptive potential. As investor interest shifts toward science-backed innovation and defense-grade infrastructure, PRSO, LXRX, PRTG, RNAZ and SIGL are fast becoming tickers to watch in 2025’s next-generation growth landscape.